BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ooijevaar RE, van Nood E, Goorhuis A, Terveer EM, van Prehn J, Verspaget HW, van Beurden YH, Dijkgraaf MGW, Keller JJ. Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature. Microorganisms 2021;9:548. [PMID: 33800841 DOI: 10.3390/microorganisms9030548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. Front Immunol 2021;12:642166. [PMID: 34163468 DOI: 10.3389/fimmu.2021.642166] [Reference Citation Analysis]
2 de Stefano MC, Mazzanti B, Vespasiano F, Lombardini L, Cardillo M. The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy. Antibiotics 2022;11:480. [DOI: 10.3390/antibiotics11040480] [Reference Citation Analysis]
3 Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. Cells 2022;11:435. [DOI: 10.3390/cells11030435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes 2022;14:2038856. [PMID: 35230889 DOI: 10.1080/19490976.2022.2038856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scand J Gastroenterol 2022;:1-10. [PMID: 35486073 DOI: 10.1080/00365521.2022.2064725] [Reference Citation Analysis]
6 Nooij S, Terveer EM; Netherlands Donor Feces Bank. Reply. Gastroenterology 2021:S0016-5085(21)03812-9. [PMID: 34863789 DOI: 10.1053/j.gastro.2021.11.036] [Reference Citation Analysis]